ATACANA GROUP Inc.’s Post

As CEO of Sinaptica Therapeutics, Ken is leading the team to advance their personalized closed-loop neuromodulation therapy for Alzheimer's, which has generated unprecedented Phase 2 sham-controlled clinical data that was recently published in Oxford journal, 'Brain.' Sinaptica has FDA Breakthrough status for its novel proprietary approach which combines rTMS, EEG, and Neuronavigation with a sophisticated ML-derived personalization engine based on a novel brain target-- the precuneus, the central hub of the Default Mode Network, a brain network involved in episodic memory. The company has completed all clinicals to date with non-dilutive funding, and is now in-process on a financing to complete the clinical product (SinaptiStim™️ ) and prepare to initiate a pivotal study in 2024. Previously to Sinaptica, Ken has 20+ years leading and growing new business ventures on both the 'Buy Side' and the 'Build Side.' He started his career in management consulting at Charles River Associates, then jumped to industry at CSL, then Baxter BioScience (now Takeda), and Boston Scientific, with leadership roles in marketing, strategy, and corporate development. At Boston Scientific's nearly $1B Neuromodulation division, he was the global commercial lead for the highly successful Cosman RF ablation business he helped acquire. He also built the division’s Strategy function, providing leadership in areas including strategic planning, BD assessment, R&D portfolio management, digital strategy, and investments in next-gen platforms & new indications. Meet Ken Mariash @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

🌐 🧠 Neuroscience News 🧠 🌐 💷 LoQus23 Therapeutics Ltd announces £35m Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease. "This financing will enable us to develop key clinical data to support the development of our exciting lead programme." David Reynolds - CEO ✅ US approves Karuna Therapeutics / Bristol Myers Squibb schizophrenia drug #Cobenfy with new mode of action. Congratulations to Daphne Zohar Bill Meury Steven Paul Steve Brannan and all those involved. 🤝 AstronauTx appoint Jane Rhodes as their CEO. "Jane has a strong track record of company formation, successful equity financing and forging large enabling Pharma partnerships, all of which will be invaluable in our next phase of growth." Tim Edwards - Chair 💶 BrainEver are looking to raise an additional €5m as part of a larger €35m Series B to launch clinical trials in 2025 to fight Charcot disease. Bernard GIlly ⏩ Ionis Pharmaceuticals, Inc. Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease. "With no approved treatments available for people living with AxD, receiving this Fast Track designation for zilganersen reflects the seriousness of this ultra-rare disease and the significant unmet need for treatment in this patient population" Eugene Schneider, Chief Clinical Development Officer #CNS #Neuroscience #Neurology

📆 As an innovative #preclinical #CNS #CRO specializing in translational in vivo #EEG, SynapCell is proud to sponsor the 7th Neuropsychiatric Drug Development Summit, to be held in Boston from Sept. 24 to 26, 2024. This event will provide a deep dive of EEGs as translational tools in neuropsychiatry and beyond: https://lnkd.in/eNfB37Wn With 20 years’ experience in preclinical EEG, SynapCell provides drug developers with decision-making capabilities to identify and test their most promising candidates: we have developed unique know-how in capturing and analyzing EEG signals, providing high-quality translational EEG biomarkers and specific models to help drug developers assess the efficacy of their compounds at the #preclinical stage. Transforming raw EEG data into valuable information for drug efficacy testing, derisking or #pharmacodynamic measurements is a solid know-how we have acquired over two decades. 👉 To schedule a meeting at the event, contact Hugo Monchal and Youness AJRAOUI. #NDDS #preclinicalresearch #drugdevelopmeent #drugefficacy #neuroscience

🎉 Exciting News from AbbVie! 🎉 AbbVie has successfully completed its acquisition of Aliada Therapeutics, marking a significant milestone in advancing treatments for Alzheimer’s disease and bolstering its neuroscience R&D capabilities. 💡 What’s New? ALIA-1758: A promising disease-modifying antibody currently in Phase 1 trials for Alzheimer's. Innovative Technology: Aliada's blood-brain barrier (BBB)-crossing platform, enhancing CNS drug delivery. 🧠 Why It Matters Alzheimer’s disease continues to challenge global healthcare systems, impacting millions worldwide. With Aliada's expertise and innovative platforms, AbbVie is taking a major step toward addressing this growing public health concern. ✨ Quote from AbbVie Leadership "With the acquisition now complete, we look forward to advancing potentially disease-modifying therapies and leveraging Aliada's novel CNS drug delivery platform." – Dawn Carlson, M.D., M.P.H., VP, Neuroscience Development This acquisition underscores AbbVie's commitment to tackling complex neurological diseases and advancing transformative solutions for patients globally. #PharmaInnovation #BiotechNews #AlzheimersResearch #Neuroscience #HealthcareInnovation #AbbVie #AliadaTherapeutics

𝐋𝐨𝐧𝐳𝐚 𝐚𝐧𝐝 𝐍𝐞𝐮𝐫𝐨𝐒𝐞𝐧𝐬𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐞 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐀𝐋𝐒 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Lonza (SIX: LONN) Lonza and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) NeuroSense Therapeutics announced a collaboration to evaluate biological changes in neurodegenerative diseases, including ALS. This partnership grants NeuroSense access to Lonza's extracellular vesicles expertise. Lonza will develop a method for measuring biomarkers from NDEs to integrate into NeuroSense's lead ALS product, PrimeC. Davide Zocco Davide Zocco, Lonza's Head of Exosomes Development, stated: "Lonza's 'Dev-on-Demand' solution provides NeuroSense with access to expert scientists for their development activities." Alon Ben-Noon Alon Ben-Noon 🇮🇱, NeuroSense's CEO, commented: "This collaboration could be a game-changer for ALS and neurodegeneration. Findings in biomarkers may advance diagnosis and treatment." NeuroSense recently reported positive Phase 2b PARADIGM trial results for PrimeC in ALS, showing a statistically significant slowing of disease progression. #NeurodegenerativeDiseases #ALSResearch #Collaboration #Biotech #Innovation #Biomarkers #Exosomes #Therapeutics #MedicalResearch #Healthcare #Neurology #ClinicalTrials #DrugDevelopment #Lonza #NeuroSense #PrimeC

🧬 in Precision Medicine: Arialys Therapeutics Emerges with $58M to Transform Neuropsychiatric Treatment TL;DR: • Launches with $58M from top investors including J&J • Developing ART5803 for anti-NMDA receptor encephalitis • Plans FDA submission for clinical trials in 2024 • Exploring applications for schizophrenia and Alzheimer's Arialys Therapeutics is pioneering an immune system-focused approach to neuropsychiatric disorders, mirroring successful precision oncology strategies. Their lead candidate, ART5803 (acquired from Astellas Pharma), shows promising preclinical results in treating brain inflammation and behavioral symptoms. Backed by industry giants including Avalon BioVentures, MPM BioImpact, and J&J's venture arm, Arialys joins a resurgent neuroscience field that's seeing renewed interest from major pharma companies. This development follows recent momentum in neuroscience, with Neumora Therapeutics' $600M+ funding and upcoming IPO, plus GSK's renewed commitment to brain disease research. 💡 What are your thoughts on the intersection of immunology and neuropsychiatry? Share your insights on this emerging therapeutic approach. #Biotech #PrecisionMedicine #Neuroscience #BiotechInnovation #DrugDevelopment #intelligencesimplified #pharma #biotech #biodatastudio

🚨𝐁𝐑𝐄𝐀𝐊𝐈𝐍𝐆: 𝐀𝐛𝐛𝐕𝐢𝐞 𝐀𝐜𝐪𝐮𝐢𝐫𝐞𝐬 𝐀𝐥𝐢𝐚𝐝𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐢𝐧 $𝟏.𝟒 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐃𝐞𝐚𝐥 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 AbbVie has announced its acquisition of Aliada Therapeutics, a privately held biotech specializing in early-stage drugs for Alzheimer’s disease. This $1.4 billion acquisition highlights AbbVie’s strategic expansion into neuroscience, underscoring the importance of Aliada’s proprietary technology that enhances blood-brain barrier penetration—a critical challenge in neurodegenerative drug development. Aliada’s approach to crossing the blood-brain barrier could be transformative for Alzheimer’s treatments, potentially improving drug delivery directly to the brain. AbbVie’s investment in this innovative technology marks a significant bet on the future of Alzheimer’s therapy, a field with vast unmet needs and considerable commercial potential. This acquisition aligns with a larger trend of major players targeting novel mechanisms in the Alzheimer’s and neuroscience space. As the industry watches AbbVie’s latest move, it reaffirms the company’s commitment to addressing neurodegenerative diseases and advancing therapeutic frontiers. #Biotech #AbbVie #AliadaTherapeutics #Alzheimers #Neuroscience #BloodBrainBarrier #Pharma

🔬 Axonis Therapeutics Raises $115M Series A for Groundbreaking Neurological Treatments TL;DR: • Major funding round co-led by Cormorant Asset Management and venBio Partners • Focus on KCC2 protein targeting for epilepsy and pain treatments • Clinical trials expected to begin this year • Signals growing investor confidence in CNS therapies Axonis is pioneering a novel approach to treating neurological disorders by enhancing KCC2 protein function - a critical regulator of brain cell activity. The science is backed by compelling genetic evidence linking KCC2 mutations to childhood epilepsies. This substantial funding follows recent industry momentum, with notable acquisitions of Karuna Therapeutics ($14B) and Cerevel Therapeutics ($9B) highlighting renewed interest in neuropsychiatry investments. Key developments: • Strategic expansion into multiple CNS indications • Strong preclinical data supporting their approach • Experienced leadership team including Harvard Medical School talent • Distinguished board additions from Cormorant and Sofinnova What are your thoughts on the future of precision neurological therapies? Share your insights on this emerging trend in CNS drug development. #Biotech #Neuroscience #VentureCapital #DrugDevelopment #Innovation #intelligencesimplified #pharma #biotech #biodatastudio

𝐂₂𝐍 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐰𝐢𝐭𝐡 𝐌𝐞𝐝𝐢𝐟𝐨𝐫𝐝 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐄𝐱𝐩𝐚𝐧𝐝 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫'𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐢𝐧 𝐉𝐚𝐩𝐚𝐧 C₂N Diagnostics, LLC (“C2N”) C2N Diagnostics announces a partnership with Mediford Corporation, a premier provider of clinical research in Japan, expanding access to C₂N Biopharma Clinical Research Services. This collaboration enhances access to C₂N’s Precivity™ line of blood tests for Alzheimer’s disease (AD) diagnosis and monitoring. The alliance with Mediford Corporation increases access to C₂N’s highly sensitive mass spectrometry-based biomolecule analysis, aiding researchers in Japan. C₂N’s expertise includes the Precivity™ line, offering high-performance blood tests for AD diagnosis, prognosis, staging, and treatment monitoring, including innovative biomarkers like MTBR-tau for detecting neurofibrillary “tau” tangles. Dr. Maki Hoshiko Maki Hoshiko joins C₂N to lead its Japan strategy and scientific collaborations, leveraging her expertise as a neuroscientist and commercialization professional. Japan's high prevalence of Alzheimer's disease underscores the importance of this expansion, with the country accounting for a significant portion of diagnosed cases globally. C₂N’s CEO, Dr. Joel Braunstein Joel Braunstein, MD, emphasizes the strategic significance of the partnership in advancing Alzheimer’s research and treatment solutions. Mediford Corporation President, Mr. Kei Shimizu, highlights C₂N’s reputation for quality and innovation in Alzheimer’s diagnostics, underscoring the value of their blood biomarker testing for clinical trial and treatment monitoring. #AlzheimersAwareness #Neurology #Biopharma #BrainHealth #MedicalInnovation #ClinicalTrials #Diagnostics #JapanHealthcare #Neuroscience #ResearchPartnership #MedTech #Biomarkers #AlzheimersPrevention

Kariya is pleased to share that our CSO Christian Hölscher will be presenting at this year’s Alzheimer's Association® International Conference (AAIC24). The talk is part of a broader drug development symposium that covers the fundamental mechanisms by which insulin and incretin-mimetics (GLP-1 analogues) impart their neuroprotective effect, and summarizes preclinical and clinical studies to provide a comprehensive overview of the therapeutic potential of these drugs in Alzheimer’s Disease and other neurodegenerative disorders. Symposium: “Neuroprotective effect of insulin and incretin mimetics (GLP-1 analogues) in neurodegenerative diseases.” Presentation: “Neuroprotective properties of GLP-1R agonists correlate with their ability to cross the BBB.” Session Chairs:  Nigel Craig (NIH), Paul Edison (Imperial) Session Presenters: Nigel Craig, Paul Edison, Christian Hölscher, Konrad Talbot, Ana Isabel Duarte, Elizabeth Rhea Time: Tuesday, July 30, 2024: 2:00 – 3:30 PM Place: Pennsylvania Convention Center, 121 ABC #AAIC #GLP1 #drugdevelopment #clinicaldevelopment #alzheimersdisease #alzheimersresearch #curealzheimersdisease #endparkinsonsdisease #cureparkinsonsdisease #parkinsonsresearch #parkinsonsdisease #movementdisorders #patientsarewaiting #hope #neuroscience #CNS